Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three months ended 31 March 2026.

Revenue and Profitability • Revenue edged up to RMB 17.00 billion, a 1.23% year-on-year increase from RMB 16.79 billion. • Operating profit fell to RMB 220.19 million, down 20.41% from RMB 276.67 million, reflecting margin pressure. • Total comprehensive income attributable to the parent slipped 7.47% to RMB 115.15 million versus RMB 124.44 million a year earlier.

Cash Flow • Net cash used in operating activities widened to an outflow of RMB 4.57 billion, compared with a RMB 3.13 billion outflow in the prior-year period, marking a 45.86% deterioration.

Balance Sheet Position • Total assets grew 3.82% quarter-to-date to RMB 59.49 billion, up from RMB 57.30 billion at the start of the period. • Equity attributable to the parent increased 1.39% to RMB 8.42 billion from RMB 8.30 billion.

Key Takeaways CNMDC delivered modest top-line growth in the first quarter of 2026, yet faced notable declines in operating profit and net income amid a sharper operating cash outflow. Asset expansion outpaced growth in shareholder equity, underscoring a need to monitor leverage and cash-generation trends in subsequent quarters.